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A B S T R A C T   
Background: Public transport (PT) users typically accumulate more physical activity (PA) than private motor 
vehicle users yet redressing physical inactivity through transport-related PA (TRPA) interventions has received 
limited attention. Further, incentive-based strategies can increase leisure-time PA but their impact on TRPA, is 
unclear. This study’s objective is to determine the impact of an incentive-based strategy on TRPA in a regional 
Australian setting. 
Methods: trips4health is a single-blinded randomised controlled trial with a four-month intervention phase and 
subsequent six-month maintenance phase. Participants will be randomised to: an incentives-based intervention 
(bus trip credit for reaching bus trip targets, weekly text messages to support greater bus use, written PA 
guidelines); or an active control (written PA guidelines only). Three hundred and fifty adults (18 years) from 
southern Tasmania will be recruited through convenience methods, provide informed consent and baseline in-
formation, then be randomised. The primary outcome is change in accelerometer measured average daily step 
count at baseline and four- and ten-months later. Secondary outcomes are changes in: measured and self-reported 
travel behaviour (e.g. PT use), PA, sedentary behaviour; self-reported and measured (blood pressure, waist 
circumference, height, weight) health; travel behaviour perspectives (e.g. enablers/barriers); quality of life; and 
transport-related costs. Linear mixed model regression will determine group differences. Participant and PT 
provider level process evaluations will be conducted and intervention costs to the provider determined. 
Discussion: trips4health will determine the effectiveness of an incentive-based strategy to increase TRPA by tar-
geting PT use. The findings will enable evidence-informed decisions about the worthwhileness of such strategies. 
Trial registration: ACTRN12619001136190. 
Universal trial number: U1111-1233-8050.   
1. Background 
Physical inactivity is one of the most significant global health con-
cerns, causing 6–10% of coronary heart disease, type 2 diabetes and 
breast and colon cancers [1]. Physical inactivity poses a similar risk for 
premature mortality as smoking and obesity and in 2013 was estimated 
to cost the international community in productivity losses and health 
care system costs INT$67.5 billion [1,2]. Despite abundant initiatives to 
support population level increases in physical activity (PA) (e.g. “Life. 
Be in it”, “This Girl Can”, “International Walk to School Day”), little 
progress has been made. For instance, the proportion of Australians 
(aged 15 years and older) adhering to PA guidelines is basically 
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unchanged since the 1980s at around 35–40% [3]. Initiatives to redress 
physical inactivity have principally focused on leisure-time and sporting 
activities, with much less attention given to other domains of PA such as 
transport [4]. 
Many international, national and state-based frameworks for PA 
promotion highlight the important impact that active travel (e.g. 
cycling, walking) supportive environments can have on daily PA [5–8]. 
Active commuters have significantly lower cardiovascular risk than 
passive commuters [9] and up to 33 min/day of PA is accumulated 
through use of public transport according to a recent systematic review 
[10]. Transport-related PA represents an attractive but under-explored 
opportunity to support individuals to make small changes that collec-
tively can positively impact population health. While transport-related 
PA is discretionary, travelling from place to place is commonly a 
necessary daily behaviour. Drawing on dual process theory, individuals 
may be more likely to persist with regular PA if it is associated with a 
habitual pattern, such as travel [11–13]. 
Incentive-based strategies have demonstrated some promise for 
improving health behaviours in adults, but relatively few high-quality 
studies have focused on PA and none specifically on incentivising pub-
lic transport use for PA gain [14–21]. In a 2017 survey on travel 
behaviour and health involving 1091 Australian adults, 42.4% of par-
ticipants rated an incentive-based strategy as likely/extremely likely to 
increase their public transport use, ranking it as one of the top three 
public transport use enhancement strategies in the survey [22]. How 
best to implement incentive-based strategies to increase public transport 
use for PA gain in real-world settings is unestablished. Behavioural 
economics theory purports that humans suffer from ‘present bias’, and 
therefore immediate rather than delayed gratification may be more 
likely to change behaviour (23,24). Behaviour change may also be more 
likely when incentives are frequent and progressively escalated [20,23, 
24]. Incentive-based strategies are also more likely to succeed when 
supported by other proven behaviour change techniques (e.g. 
goal-setting, self-monitoring, social support [25]). 
trips4health is a single-blinded randomised controlled trial designed 
to fill a knowledge gap and respond to a stakeholder identified need 
regarding the impact of an incentive-based strategy on public transport 
use for PA gain. The study findings will benefit service providers, poli-
cymakers and practitioners. 
2. Objectives 
The aim of trips4health is to establish the impact of an incentive- 
based strategy (rewarding greater public transport use) on transport- 
related PA. 
3. Trial design 
Single-blinded controlled trial. 
4. Materials and methods 
Participants, interventions and outcomes. 
5. Study setting 
The study will be implemented within the greater area of Hobart, the 
state capital of Tasmania (Fig. 1). Tasmania is a regional island state of 
Australia with approximately 510,000 people of which just under half 
live in the study area [26]. Tasmania has some of the highest rates of 
chronic disease in Australia and is characterised by high levels of so-
cioeconomic disadvantage [27]. The only mode of public transport is 
bus, with metropolitan services predominantly offered by one provider 
(Fig. 1). In 2016, 5.3% of employed residents within the greater Hobart 
area were estimated to commute by bus as a single method of transport, 
compared with 76% estimated to commute by driving a car [28]. 
Fig. 1. Study Setting: The Greater Hobart area with public transport accessibility identified. 
Hobart city; Urban public transport zone; Non-urban public transport zones; Greater Hobart Region. 
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6. Eligibility criteria 
Prospective participants’ eligibility will be determined via an online 
or telephone screening questionnaire (Fig. 2). Inclusion criteria include: 
 18 years old; sufficient English proficiency to provide informed con-
sent; living in Southern Tasmania; able to access an urban Tasmania bus 
service (participant defined); making trips by motor vehicle that could 
be made by bus; current infrequent bus user (on average  2 trips per 
week in the past six months); possession or willingness to possess a 
public transport smartcard; willingness for the public transport provider 
and the researchers to access smartcard data; possession of a mobile 
phone. Exclusion criteria include: intending to move house or work 
location whereby an urban bus service in Southern Tasmania will be 
inaccessible within the 10-month study period; currently engaged in or 
planning to engage in other incentive-based programs to enhance public 
transport use; pregnancy; a health condition that prevents walking; a 
health condition that prevents bus use; and a planned activity that 
would prevent bus use for greater than two weeks during the four month 
intervention phase of the 10 month study period e.g. surgery, extended 
holiday. 
7. Interventions 
The trips4health study has a four-month intervention phase followed 
by a six month maintenance phase (Fig. 2). While there is debate in the 
literature about the minimum length of time needed for habits to form 
[29] a four-month intervention phase was selected as it allows three 
months for behaviour change to reach automaticity and one month for 
maintenance or ‘tapering off’, where contact and support is gradually 
withdrawn in preparation for intervention cessation [30] (Table 1). 
Fig. 2. Overview of participant timeline.  
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Using a ‘gain-framed’ approach (i.e. rewarding positive behaviours), 
participants in the intervention group will have bus trip targets from 
weeks 1–16 which escalate over the course of the intervention so that 
targets become more difficult to reach but incentive values increase. If 
the bus trip target is met (confirmed through objective smartcard data), 
participants receive bus trip credit (through their smartcard). The credit 
received will be commensurate with the participant’s default/usual fare 
type that they were required to set when applying for their smartcard. 
The price range (AUD$) of the different fare types is $1.92 to $5.76 (a 
concessional fare through to a full-fare with travel across multiple 
zones). The maximum credit a participant can receive by the end of the 
16-week intervention phase is $103.68 if travelling on a concessional 
fare and if travelling on a full-fare either $151.20, $207.36 or $311.04 as 
per their default fare type. Participants will be notified by a weekly 
email whether they have met or have not met their target, the smartcard 
credit they have received (if any) and the following week’s target. 
Participants will be aiming to achieve five one-way bus trips per week by 
the end of the intervention. To assist participants to achieve the weekly 
targets and, consistent with best practice, incentives will be supported 
by other behaviour change techniques (e.g. information on conse-
quences of behaviour to the individual, setting graded tasks, goal 
setting, social support), delivered via weekly mobile text messages [31]. 
Development of the text messages was underpinned by the Behaviour 
Change Technique Taxonomy, informed by our previous qualitative 
work on transport behaviour and PA and from an incentive-based study 
designed to increase weekly leisure-time PA and reduce sitting time [14, 
22,32]. Text messages will be offered to the intervention group only. 
This can help to counter the potential risk that incentives alone may 
undermine intrinsic motivation in the absence of broader behavioural 
support. It has been argued that incentives aimed at addressing habitual 
behaviours such as physical inactivity may be more impactful if deliv-
ered as part of effective behaviour change programs [31]. Both the 
intervention and control groups will receive printed versions of Aus-
tralia’s Physical Activity and Sedentary Behaviour Guidelines [33]. 
Educational materials have been selected as an active control to help 
engage and retain the control group – alone, this type of cognitive 
strategy is unlikely to influence PA behaviour [34]. All intervention 
support will be provided by a member of the research team. 
8. Outcomes 
The primary outcome is change in average daily step count measured 
by accelerometer over seven days at baseline (Timepoint 1/T1), 
immediately post-intervention (week 17/18; Timepoint 2/T2; primary 
endpoint) and at the end of the maintenance phase (week 41/42; 
Timepoint 3/T3). The secondary outcomes are change in: self-reported 
and measured (via a smartphone app collected over seven days and 
smartcard data) travel behaviour (e.g. mode (e.g. motor vehicle), fre-
quency and duration); perspectives on travel behaviour (e.g. enablers 
and barriers); self-reported out of pocket transport-related expenses; 
self-reported work productivity; self-reported commute time to work/ 
study location; self-reported commute time by different transport 
modes; self-reported PA (transport, leisure, occupational, domestic, 
total) (mins/week) and sedentary behaviour (sitting) using the Inter-
national Physical Activity Questionnaire – Long form (IPAQ – L) sup-
plemented with additional questions in the study-specific survey [35]; 
accelerometer measured minutes/week of PA, sedentary behaviour and 
PA intensity; measured blood pressure using a validated automated 
blood pressure device and waist circumference determined by a mea-
surement tape; body mass index calculated from measured (using a 
stadiometer and digital scales) or self-reported height and weight; and 
self-reported health, with quality of life (QoL) measured by the Assess-
ment of Quality of Life (AQoL)-8D [36,37]. Costs incurred by the public 
transport provider to implement the intervention will be measured by 
data supplied by the provider at trial completion. All self-reported out-
comes will be measured through the study-specific survey at all three 
timepoints. 
9. Sample size 
Sample size calculations are based on the comparison of the primary 
outcome in the control versus intervention group. The calculations are 
based on mean and standard deviation of daily steps as measured by 
accelerometer (8000  3500) based on data from a sample of partici-
pants using the same measure [38]. The assumed correlation between 
baseline and at 10 months follow-up was 0.7, with a high level of sta-
bility expected between baseline and follow-up because PA typically 
Table 1 
trips4health intervention schedule.   
Intervention 
phase 
Bus trip 
targets 
Smartcard credit available (all 
zones full-farea) 
Smartcard credit available (all zones 
concessional fareb) 
Text message 
frequency 
Within 2 weeks pre-intervention Baseline survey, smartcard data, clinic assessment, accelerometer, travel behaviour smartphone app 
Week 1 Getting started 1 $5.76 $1.92 x 2 
Week 2 Getting started 1 $5.76 $1.92 x 2 
Week 3 Slowly 
increasing 
2 $11.52 $3.84 x 2 
Week 4 Slowly 
increasing 
2 $11.52 $3.84 x 2 
Week 5 Moving along 3 $17.28 $5.76 x 2 
Week 6 Moving along 3 $17.28 $5.76 x 2 
Week 7 Moving along 3 $17.28 $5.76 x 2 
Week 8 Moving along 3 $17.28 $5.76 x 2 
Week 9 Aiming high 4 $23.04 $7.68 x 2 
Week 10 Aiming high 4 $23.04 $7.68 x 2 
Week 11 Aiming high 4 $23.04 $7.68 x 2 
Week 12 Aiming high 4 $23.04 $7.68 x 2 
Week 13 Keeping up 5 $28.80 $9.60 x 1 
Week 14 Keeping up 5 $28.80 $9.60 x 1 
Week 15 Keeping up 5 $28.80 $9.60 x 1 
Week 16 Keeping up 5 $28.80 $9.60 x 1 
Total 54 $311.04 (AUD) $103.68 (AUD) 28 
Week 17 or 18 Post-intervention survey, smartcard data, clinic assessment, accelerometer, travel behaviour smartphone app 
Week 41 or 42 >(10 months from 
baseline) 
Follow-up survey, smartcard data, clinic assessment, accelerometer, travel behaviour smartphone app  
a most expensive fare type. 
b cheapest fare type. 50% of the public transport provider’s adult passengers travel on a concessional fare. 
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tracks well over shorter periods of time (e.g. weeks and months) [39]. A 
high level of stability is expected between baseline and at 10 months 
follow-up because the unit of analysis will be based on average daily 
steps. A total sample of 300 participants would provide 80% power with 
α  0.05 to detect a difference of 624 steps/day (an 8% change). 
Allowing for expected attrition (based on a previous related PA 
incentives-based study [14]), the plan is to recruit 350 participants. 
10. Recruitment 
Participants will be recruited through social/traditional media, 
workplaces, word-of-mouth, bus advertising, professional networks, and 
co-promotion through other related projects. To minimise self-selection 
based on a preference for PA, promotional materials will be framed to 
focus on health generally, noting the potential for smartcard credit (i.e. 
‘Does taking the bus  better health? Want to earn over 50 free bus 
trips?’). Recruitment materials will direct potential participants to a 
study website and provide email and telephone contact details. The 
study website will provide more detailed information, including a link to 
the screening survey. 
The recruitment phase will occur in two waves, with Wave 1 
commencing in September 2019 and Wave 2 commencing in February 
2020. The reason for conducting recruitment in two stages is to reduce 
resource burden and to lessen the impact of seasonal variation in PA and 
public transport use. Each recruitment wave is expected to take up to 
three months but will be extended if necessary. The positive response 
(n  1091) with minimal advertising in a two-week period in our 2017 
transport and physical activity behaviour project indicates high feasi-
bility of this approach [22]. Participants will be directed to register their 
interest via the study website page, email or telephone contact. To 
facilitate recruitment, all participants (irrespective of group allocation) 
will receive smartcard credit to a maximum value of $30 (AUD) as study 
compensation. Compensation will be commensurate with participation 
and is independent of the incentives scheme: completion of the baseline 
assessment (T1)  $5 credit; completion of the post-intervention 
assessment (T2)  $10 credit; and completion of the follow-up assess-
ment (T3)  $15 credit. Greater compensation for greater participation 
will be employed as a strategy to enhance retention and mitigate 
drop-out, particularly among the control group. This small amount of 
compensation was considered unlikely to alter usual travel behaviour. 
11. Assignment of interventions 
11.1. Allocation 
After completion of the baseline assessment (T1), participants will be 
randomly allocated to the control or intervention arm. The allocation 
sequence will be created using computer-generated random numbers on 
a 1:1 ratio without stratification. Randomisation will be conducted in 
blocks of four, the details of which will be unavailable to research team 
members who enrol participants in the respective study arms. 
11.2. Blinding 
Due to the nature of the intervention, participants cannot be blinded 
to treatment allocation. All members of the research team will be blin-
ded except for two research assistants (RAs). The unblinded RAs will be 
responsible for enrolling participants, assigning participants to the 
control or intervention arms according to the treatment allocation 
sequence generated through the software Research Electronic Data 
Capture (REDCap, Version 8.5.19, Nashville, Tennessee, USA), inform-
ing participants of the requirements of being in the respective study arm, 
advising participants in the intervention arm if they have met their 
weekly bus trip target and the subsequent weekly target, coordinating 
clinic assessments and overall be the main contact point for participants. 
The unblinded RAs will not be involved in conducting the post 
randomisation clinic assessments at T2 and T3 or data analysis. The 
research team member who creates the randomisation sequence will 
have no contact with participants and will not be involved with data 
collection or analysis. There are no foreseen circumstances by which 
unblinding of other research team members would need to occur. 
12. Data collection, management and statistical methods 
12.1. Data collection methods 
All participants will complete a baseline assessment (T1), an 
assessment immediately post-intervention (4 months post intervention 
commencement, T2) and a follow-up assessment six months post- 
intervention (10 months post-intervention commencement, T3) to 
assess if any changes are sustained once incentives are ceased. To 
maximise participation and ensure acceptable levels of participant 
burden, a stepped approach will ensure a minimum amount of data 
collection from all participants, with more burdensome measures 
related to the secondary outcomes from those willing and able to do so 
(Table 2). Surveys will be offered electronically, with hard copies pro-
vided only if necessary. The survey will include demographic, travel, PA, 
health and economic related questions. The IPAQ-L is included in the 
survey because it is reliable, widely used and separates leisure and 
transport-related PA [35]. The AQoL–8D is a reliable and valid QoL 
evaluation tool, has Australian population norms, is sensitive to minor 
changes in QoL and has been included in the survey to complement the 
health-related questions and to attain health state utility values [36,37]. 
Permission to use participants’ smartcard data is an eligibility require-
ment and will be sought during the screening and consent process. Data 
collected from the smartcard includes the date and time (at point of 
boarding only) of each trip. Smartcard data will be retrieved for the two 
months prior to commencement of the study (for participants with an 
existing smartcard) to enable objective assessment of participants’ usual 
bus use. Participants with a smartphone will be asked to download the 
state-of-the-art trips4health smartphone app. The app uses Global Posi-
tioning System (GPS) technology to passively track travel behaviour and 
automatically infer trips, together with start/end times and travel 
duration. The app is designed to overcome known limitations of tradi-
tional self-report methods (e.g., travel diaries), which are highly 
burdensome, and among other limitations, poor at picking up short, 
incidental active transport trips, a critical issue for this study [40]. 
Participants are prompted each day over a seven-day period to confirm 
trips are genuine and provide travel mode and purpose through a simple 
interface with each trip taking a few seconds to code. The app will be 
introduced at the first clinic assessment, providing a unique face-to-face 
opportunity to explain how the app works as well as easing known 
barriers, particularly around privacy. 
Physical measurements (blood pressure, height, weight, waist 
circumference) will be taken and accelerometers (ActiGraph GT3X and 
GT3X) administered at the clinic assessments. All clinic assessments 
will be conducted at a single clinical research facility. To ensure high 
quality data collection, respective research team members will be 
trained according to standardised protocols. Height will be measured 
using a fixed stadiometer to the nearest 0.1 cm, and weight measured to 
the nearest 0.1 kg. Waist circumference will be measured at the level of 
the narrowest point between the lower costal (10th rib) border and the 
Table 2 
Stepped levels of assessment participation.  
Level of 
assessment 
Survey Smartcard 
data 
Accelerometer trips4health 
app 
Physical 
measures 
Minimum ✓ ✓ ✓   
Medium ✓ ✓ ✓ ✓   
✓ ✓ ✓  ✓ 
High ✓ ✓ ✓ ✓ ✓  
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iliac crest using a Figure Finder tape measure. Three blood pressure 
readings at 1-min intervals will be taken after 5 min of rest (feet flat on 
the floor, legs uncrossed, back supported, shoulders and arms relaxed, 
forearms resting on chair/table) using an automated Omron HEM 907 
blood pressure device. 
Participants will be asked to wear a wrist-worn accelerometer for 
seven consecutive days, as recommended [41]. Accelerometers accu-
rately and reliably measure step count, PA frequency, intensity and 
duration and sedentary behaviour [42–44]. Accelerometers will be is-
sued where possible at clinic assessments, but for those unable or un-
willing to attend a clinic, accelerometers will be mailed to participants 
in padded postage packs with instructions provided via telephone. As 
well as verbal instructions, all participants will receive detailed written 
instructions for wearing the accelerometer including monitor place-
ment, how to return the monitor via a reply-paid padded postage pack 
and contact details of the study team, and a brief diary for noting the 
date of wear and any notable comments (e.g. unwell, forgot to wear). 
Monitors not returned will be followed up via telephone and email until 
received. 
12.2. Data management 
Participants will complete the survey through REDCap. Physical 
measurements will be entered into REDCap by a trained research team 
member. To ensure data quality, range and aberrant data value checks 
will be set up in REDCap to highlight possible errors. Electronic data 
collected through the app will be stored in an isolated, single purpose, 
secure database hosted by Tourism Research Technology (Tasmania, 
Australia), behind a firewall with limited and restricted organisational 
access and with appropriate deployment, security and permissions 
configurations. Once downloaded by the research team, the app data 
along with all other data will be stored on a secure, password-protected 
database behind University firewalls. Only members of the research 
team involved in data analysis will have access to the research data. This 
study is part of an intended program of work that will take place over 
several years. For this reason, the data will be kept indefinitely and for 
no less than 5 years. Participants can give optional consent for indefinite 
storage of their data. Any data destruction will be via deletion of elec-
tronic files. Deidentified data may be used by researchers outside of the 
investigator team provided that due ethics processes are adhered to. 
12.3. Statistical methods 
Quantitative Evaluation: Descriptive statistics (means and pro-
portions) will characterise the outcomes according to group allocation. 
Participant characteristics will be described and compared across 
groups. In the unlikely event that there is an uneven distribution of 
participant characteristics (e.g. gender, age, education) across the con-
trol and intervention groups resulting from chance (rather than bias) 
[45], consideration will be given to clinical meaningfulness and the size 
of any imbalances that may have occurred [46]. Comparisons will also 
be made with the general population with the purpose of informing 
conclusions about the generalisability of the participant groups. Linear 
mixed model (LMM) regression will compare differences in average 
daily step count (primary outcome) between control and intervention 
groups. LMM will also be used to compare differences between the 
control and intervention groups regarding the secondary outcomes. 
LMMs allow for missing outcome data and provide methods to account 
for correlated observations. Analyses will be undertaken on an 
intention-to-treat basis. 
Accelerometer data will be collected using 60-s epochs, and Freedson 
1998 equations used to determine cutpoints for sedentary, light, mod-
erate and vigorous intensity physical activities [47]. The impact of 
applying the criteria of minimum daily wear time (10 h/day), minimum 
number of days worn (4 days) and minimum number of weekdays and 
weekend days (3 weekdays and 1 weekend day), as well as consideration 
of daily wear time values, will be examined in sensitivity analyses [48]. 
Self-reported domain-specific data from the IPAQ will enable ex-
amination of any displacement of leisure-time PA for time spent on 
public transport and/or in transport-related PA, which could potentially 
explain null findings. 
Secondary analyses to better understand possible enabling factors 
that may influence adherence to protocols and intervention effective-
ness will be undertaken so that appropriate recommendations can be 
made about future rollout or upscaling of the intervention. 
Economic Evaluation: Non-research related resources associated 
with the implementation of the intervention will be documented and the 
comparative costs and benefits of the intervention relative to the control 
group will be assessed. The primary outcome of the economic analysis is 
a cost comparison between intervention and control groups, that is, a 
cost-benefit analysis with all costs and benefits expressed in monetary 
(AUD$) terms. 
Modelled analyses will be undertaken to assess the financial impli-
cations of broader implementation rollout and intervention upscaling. 
Personal time (e.g. more/less time spent commuting), productivity and 
outlay (e.g. walking equipment, fuel, parking) costs will also be 
evaluated. 
Process Evaluation: This will assess the fidelity and quality of 
implementation, clarify causal mechanisms and identify contextual 
factors associated with outcome variation [49]. Using the Medical 
Research Council UK’s framework [50] designed for examining complex 
public health interventions, intervention acceptability at completion of 
the intervention will be assessed (T2) through face-to-face or telephone 
interviews with intervention group participants (n  20 or until satu-
ration of major themes) who did and did not reach bus trip targets. 
Participants in the intervention arm will be asked if they are willing to 
participate in an interview when completing the survey at T2. Interviews 
will be timed to coincide with clinic attendance. The recruitment and 
implementation impact for the public transport provider will be deter-
mined through face-to-face interviews or group discussion with key 
personnel (n 5) at key points during the implementation of the 
intervention (i.e. intervention development, mid-intervention and 
intervention completion). Process evaluation items will be included in 
all three surveys for all intervention group participants. 
13. Monitoring 
13.1. Data monitoring 
trips4health is a behaviour change study that does not require par-
ticipants to undertake risky clinical procedures or medication regimens. 
For this reason, a Data Monitoring Committee was considered unnec-
essary, likewise the development of an interim analysis plan and stop-
ping guidelines. 
13.2. Harms 
PA intervention studies pose minimal risk to participants [51]. 
Although unlikely, the most common PA intervention study-related 
adverse events are minor musculoskeletal injuries [51]. Adverse 
events reported to members of the research team will be logged in 
REDCap, reviewed by the chief investigator to determine the appro-
priate action and reported to the relevant ethics committee. 
At study completion, participants will be provided with a feedback 
letter summarising their health information (including PA, body mass 
index, waist circumference, blood pressure). Participants will be 
encouraged to share this summary information with their health care 
practitioner, especially if values are outside normal limits. Participants 
will only be provided with information about their health at the clinic 
assessments if their blood pressure exceeds 140/90 mmHg and under 
such circumstances they will be encouraged to see their health 
practitioner. 
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13.3. Auditing 
After approximately 10% of the total sample have completed week 
two of the intervention phase, an unblinded member of the research 
team will conduct an audit to ensure all documentation has been 
completed and appropriately managed and that the study is being 
operationalised correctly (e.g. consent forms signed and stored, ran-
domisation process working, surveys complete, data stored appropri-
ately, correspondence accurate and timely, bus trip incentives correctly 
allocated). 
14. Ethics and dissemination 
14.1. Protocol amendments 
Any changes made to the protocol will be submitted to the Tasma-
nian Health and Medical Human Research Ethics Committee for 
approval. Relevant parties will be alerted to protocol changes where 
necessary. Participants will be asked to re-consent if any protocol 
changes are made that may directly impact them (e.g. changed eligi-
bility criteria). 
14.2. Consent or assent 
Participants will provide consent electronically through REDCap or 
in person with research staff when attending the first clinic (T1). Con-
sent forms will be stored with study data. 
14.3. Confidentiality 
Access to administrative data (e.g. names, telephone numbers, email 
addresses) will be limited to research team members on a need to know 
basis. For the purpose of data cleaning and analysis, research data will 
be kept separately from administrative information. Participants will be 
assigned a unique identifier and only the unique identifier will be used 
throughout data cleaning and analysis. Only investigators will have 
access to the final de-identified trial data. Reports, publications and 
presentations arising from the study will not include any information 
that would enable the identification of participants. 
14.4. Dissemination policy 
Participants will have the option of being provided with a summary 
of findings and alerted to any publicly available reports produced. At the 
end of the study they will also be offered summary personal information. 
Findings will be disseminated through traditional academic path-
ways including conferences and peer-reviewed journals. A strategic and 
inclusive knowledge transfer strategy will ensure that findings are 
disseminated through appropriate professional mechanisms (e.g. State 
government departments, local government, advisory councils, national 
PA networks) and delivered in formats to maximise policy and practice 
impact and community benefit [52]. The knowledge transfer strategy 
will be developed in consultation with key stakeholders. 
15. Discussion 
trips4health responds to calls for more trial evidence examining the 
relationship between PA and transport behaviour and PA interventions 
that can be scaled up [4,53]. It will also address lack of investigation into 
the role of incentives-based interventions for increasing PA, particularly 
transport-related PA. 
The comprehensive analysis framework includes both objective and 
subjective measures of travel and PA behaviour (including mediators), 
economics, health economics and process evaluation which will result in 
a rich data set, enabling evidence-based decision making within policy 
and practice settings. The use of an implementation science framework 
is another strength of the study design and will ensure that key stake-
holders receive the information they need and in the desired format to 
implement the findings for maximum effect [52]. 
Physical inactivity is pandemic, causing substantive individual and 
social impact. Redressing population level physical inactivity is widely 
prioritised but efforts to correct the behaviour have predominantly 
focused on leisure-time PA and have been largely unsuccessful. trip-
s4health addresses a research gap by investigating novel and scalable 
ways to increase PA in real-world settings. 
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available from the corresponding author on reasonable request with 
appropriate approvals. 
Funding 
The study was funded by a National Health and Medical Research 
Council Partnership Project (APP1152999). VC is supported by a Na-
tional Heart Foundation of Australia Future Leader Fellowship 
(2016–2020, ID 100444). 
Declaration of competing interest 
The authors declare that they have no competing interests. 
Acknowledgements 
The authors would like to acknowledge the administrative support 
provided by Bruna Silva Ragaini. 
References 
[1] I.M. Lee, E.J. Shiroma, F. Lobelo, P. Puska, S.N. Blair, P.T. Katzmarzyk, et al., Effect 
of physical inactivity on major non-communicable diseases worldwide: an analysis 
of burden of disease and life expectancy, Lancet 380 (9838) (2012) 219–229. 
[2] D. Ding, K.D. Lawson, T.L. Kolbe-Alexander, E.A. Finkelstein, P.T. Katzmarzyk, 
W. van Mechelen, et al., The economic burden of physical inactivity: a global 
analysis of major non-communicable diseases, Lancet 388 (10051) (2016) 
1311–1324. 
[3] J. Chau, T. Chey, S. Burks-Young, L. Engelen, A. Bauman, Trends in prevalence of 
leisure time physical activity and inactivity: results from Australian National 
Health Surveys 1989 to 2011, Aust. N. Z. J. Publ. Health 41 (6) (2017) 617–624. 
[4] A.E. Bauman, R.S. Reis, J.F. Sallis, J.C. Wells, R.J. Loos, B.W. Martin, et al., 
Correlates of physical activity: why are some people physically active and others 
not? Lancet 380 (9838) (2012) 258–271. 
[5] National Heart Foundation of Australia, Blueprint for an Active Australia, Heart 
Foundation, 2014. 
[6] Government of Western Australia, Active Living for All: A Framework for Physical 
Activity in Western Australia 2012-2016 Western Australia, 2011. 
[7] Global Advocacy Council for Physical Activity, The Toronto Charter for Physical 
Activity: A Global Call to Action, International Society for Physical Activity and 
Health, 2010. 
[8] Premier’s Physical Activity Council, Tasmania’s Plan for Physical Activity 2011- 
2021, Tasmanian Government, Hobart, 2011. 
[9] M. Hamer, Y. Chida, Active commuting and cardiovascular risk: a meta-analytic 
review, Prev. Med. 46 (1) (2008) 9–13. 
[10] C. Rissel, N. Curac, M. Greenaway, A. Bauman, Physical activity associated with 
public transport use–a review and modelling of potential benefits, Int. J. Environ. 
Res. Publ. Health 9 (7) (2012) 2454–2478. 
M.J. Sharman et al.                                                                                                                                                                                                                            
Contemporary Clinical Trials Communications 19 (2020) 100619
8
[11] J.S. Evans, K.E. Stanovich, Dual-process theories of higher cognition: advancing the 
debate, Perspect. Psychol. Sci. 8 (3) (2013) 223–241. 
[12] P. Sheeran, P.M. Gollwitzer, J.A. Bargh, Nonconscious processes and health, Health 
Psychol. 32 (5) (2013) 460–473. 
[13] F. Strack, R. Deutsch, Reflective and impulsive determinants of social behavior, 
Pers. Soc. Psychol. Rev. 8 (3) (2004) 220–247. 
[14] K. Ball, R.F. Hunter, J.L. Maple, M. Moodie, J. Salmon, K.L. Ong, et al., Can an 
incentive-based intervention increase physical activity and reduce sitting among 
adults? the ACHIEVE (Active Choices IncEntiVE) feasibility study, Int. J. Behav. 
Nutr. Phys. Activ. 14 (1) (2017) 35. 
[15] J.C.M. Barte, G.C.W. Wendel-Vos, A systematic review of financial incentives for 
physical activity: the effects on physical activity and related outcomes, Behav. 
Med. 43 (2) (2017) 79–90. 
[16] E.A. Finkelstein, D.S. Brown, D.R. Brown, D.M. Buchner, A randomized study of 
financial incentives to increase physical activity among sedentary older adults, 
Prev. Med. 47 (2) (2008) 182–187. 
[17] J. Harland, M. White, C. Drinkwater, D. Chinn, L. Farr, D. Howel, The Newcastle 
exercise project: a randomised controlled trial of methods to promote physical 
activity in primary care, BMJ 319 (7213) (1999) 828–832. 
[18] E. Mantzari, F. Vogt, I. Shemilt, Y. Wei, J.P. Higgins, T.M. Marteau, Personal 
financial incentives for changing habitual health-related behaviors: a systematic 
review and meta-analysis, Prev. Med. 75 (2015) 75–85. 
[19] R.R. Wing, R.W. Jeffery, N. Pronk, W.L. Hellerstedt, Effects of a personal trainer 
and financial incentives on exercise adherence in overweight women in a 
behavioral weight loss program, Obes. Res. 4 (5) (1996) 457–462. 
[20] E.A. Finkelstein, M. Bilger, D. Baid, Effectiveness and cost-effectiveness of 
incentives as a tool for prevention of non-communicable diseases: a systematic 
review, Soc. Sci. Med. 232 (2019) 340–350. 
[21] A. Martin, M. Suhrcke, D. Ogilvie, Financial incentives to promote active travel: an 
evidence review and economic framework, Am. J. Prev. Med. 43 (6) (2012) 
e45–e57. 
[22] M.J. Sharman, A. Lyth, K.A. Jose, B.S. Ragaini, L. Blizzard, F.H. Johnston, et al., 
Acceptability and perceived feasibility of strategies to increase public transport use 
for physical activity gain - a mixed methods study, Health Promot. J. Aust. (2019), 
https://doi.org/10.1002/hpja.292 online ahead of print. 
[23] T. O’Donoghue, M. Rabin, The economics of immediate gratification, J. Behav. 
Decis. Making 13 (2) (2000) 233–250. 
[24] R. Thaler, Toward a positive theory of consumer choice, J. Econ. Behav. Organ. 1 
(1) (1980) 39–60. 
[25] E.L. Bird, G. Baker, N. Mutrie, D. Ogilvie, S. Sahlqvist, J. Powell, Behavior change 
techniques used to promote walking and cycling: a systematic review, Health 
Psychol. 32 (8) (2013) 829–838. 
[26] Australian Bureau of Statistics, 0 Census of Population and Housing: Reflecting 
Australia - Stories from the Census, 2016 - Snapshot of Australia. Canberra, 2016, 
2071. 
[27] State of Tasmania, State of Public Health, Tasmania, Population Health, 
Department of Health and Human Services, 2013, 2013. 
[28] Australian Bureau of Statistics, More than Two in Three Drive to Work, Census 
Reveals, 2017 [cited 2020 31 January 2020]. 
[29] K.G. Volpp, A.B. Troxel, M.V. Pauly, H.A. Glick, A. Puig, D.A. Asch, et al., 
A randomized, controlled trial of financial incentives for smoking cessation, 
N. Engl. J. Med. 360 (7) (2009) 699–709. 
[30] P. Lally, C.H.M. van Jaarsveld, H.W.W. Potts, J. Wardle, How are habits formed: 
modelling habit formation in the real world, Eur. J. Soc. Psychol. 40 (6) (2010) 
998–1009. 
[31] T.M. Marteau, R.E. Ashcroft, A. Oliver, Using financial incentives to achieve 
healthy behaviour, BMJ 338 (2009) 1415. 
[32] S. Michie, M. Richardson, M. Johnston, C. Abraham, J. Francis, W. Hardeman, et 
al., The behavior change technique taxonomy (v1) of 93 hierarchically clustered 
techniques: building an international consensus for the reporting of behavior 
change interventions, Ann. Behav. Med. 46 (1) (2013) 81–95. 
[33] Australian Department of Health, Australia’s Physical Activity and Sedentary 
Behaviour Guidelines for Adults (18-64 Years), Australian Government Department 
of Health, Canberra, 2014. 
[34] V.S. Conn, A.R. Hafdahl, D.R. Mehr, Interventions to increase physical activity 
among healthy adults: meta-analysis of outcomes, Am. J. Publ. Health 101 (4) 
(2011) 751–758. 
[35] C.L. Craig, A.L. Marshall, M. Sjostrom, A.E. Bauman, M.L. Booth, B.E. Ainsworth, et 
al., International physical activity questionnaire: 12-country reliability and 
validity, Med. Sci. Sports Exerc. 35 (8) (2003) 1381–1395. 
[36] A. Maxwell, M. Ozmen, A. Iezzi, J. Richardson, Deriving population norms for the 
AQoL-6D and AQoL-8D multi-attribute utility instruments from web-based data, 
Qual. Life Res. 25 (12) (2016) 3209–3219. 
[37] J. Richardson, A. Iezzi, M.A. Khan, A. Maxwell, Validity and reliability of the 
Assessment of Quality of Life (AQoL)-8D multi-attribute utility instrument, Patient 
7 (1) (2014) 85–96. 
[38] A.H. Chu, S.H. Ng, M. Paknezhad, A. Gauterin, D. Koh, M.S. Brown, et al., 
Comparison of wrist-worn Fitbit Flex and waist-worn ActiGraph for measuring 
steps in free-living adults, PLoS One 12 (2) (2017) e0172535. 
[39] W. Van Mechelen, H. Kemper, Habitual Physical Activity in Longitudinal 
perspective. The Amsterdam Growth Study: A Longitudinal Analysis of Health, 
Fitness and Lifestyle. Amsterdam, Human Kinetics, 1995. 
[40] S. Greaves, A. Ellison, R. Ellison, D. Rance, C. Standen, C. Rissel, et al., A web-based 
diary and companion smartphone app for travel/activity surveys, Transport. Res. 
Procedia 11 (2015) 297–310. 
[41] K. Corder, S. Brage, U. Ekelund, Accelerometers and pedometers: methodology and 
clinical application, Curr. Opin. Clin. Nutr. Metab. Care 10 (5) (2007) 597–603. 
[42] A.P. Hills, N. Mokhtar, N.M. Byrne, Assessment of physical activity and energy 
expenditure: an overview of objective measures, Front. Nutr. 1 (2014) 5. 
[43] D.R. Lubans, K. Hesketh, D.P. Cliff, L.M. Barnett, J. Salmon, J. Dollman, et al., 
A systematic review of the validity and reliability of sedentary behaviour measures 
used with children and adolescents, Obes. Rev. 12 (10) (2011) 781–799. 
[44] J.A. Lee, S.M. Williams, D.D. Brown, K.R. Laurson, Concurrent validation of the 
Actigraph gt3x, Polar Active accelerometer, Omron HJ-720 and Yamax 
Digiwalker SW-701 pedometer step counts in lab-based and free-living settings, 
J. Sports Sci. 33 (10) (2015) 991–1000. 
[45] D.G. Altman, C.J. Dore, Randomisation and baseline comparisons in clinical trials, 
Lancet 335 (8682) (1990) 149–153. 
[46] D.G. Altman, Comparability of randomised groups, J. R. Stat. Soc. - Ser. D 
Statistician 34 (1) (1985) 125–136. 
[47] P.S. Freedson, E. Melanson, J. Sirard, Calibration of the computer science and 
applications, Inc. accelerometer, Med. Sci. Sports Exerc. 30 (5) (1998) 777–781. 
[48] C.E. Matthews, B.E. Ainsworth, R.W. Thompson, D.R. Bassett Jr., Sources of 
variance in daily physical activity levels as measured by an accelerometer, Med. 
Sci. Sports Exerc. 34 (8) (2002) 1376–1381. 
[49] P. Craig, P. Dieppe, S. Macintyre, S. Michie, I. Nazareth, M. Petticrew, et al., 
Developing and evaluating complex interventions: the new Medical Research 
Council guidance, BMJ 337 (2008) a1655. 
[50] G.F. Moore, S. Audrey, M. Barker, L. Bond, C. Bonell, W. Hardeman, et al., Process 
evaluation of complex interventions: Medical Research Council guidance, BMJ 350 
(2015) h1258. 
[51] M. Ory, B. Resnick, P.J. Jordan, M. Coday, D. Riebe, C. Ewing Garber, et al., 
Screening, safety, and adverse events in physical activity interventions: 
collaborative experiences from the behavior change consortium, Ann. Behav. Med. 
29 (Suppl) (2005) 20–28. 
[52] H. Koorts, E. Eakin, P. Estabrooks, A. Timperio, J. Salmon, A. Bauman, 
Implementation and scale up of population physical activity interventions for 
clinical and community settings: the PRACTIS guide, Int. J. Behav. Nutr. Phys. 
Activ. 15 (1) (2018) 51. 
[53] R.S. Reis, D. Salvo, D. Ogilvie, E.V. Lambert, S. Goenka, R.C. Brownson, et al., 
Scaling up physical activity interventions worldwide: stepping up to larger and 
smarter approaches to get people moving, Lancet 388 (10051) (2016) 1337–1348. 
M.J. Sharman et al.                                                                                                                                                                                                                            
